Diagnosis and Management of Castleman Disease
Open Access
- 1 November 2019
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 17 (11.5) , 1417-1419
Abstract
Castleman disease is a heterogeneous nonmalignant lymphoproliferative disorder. Major distinctions include unicentric versus multicentric presentation; hyaline vascular, plasmacytic, or mixed pathology; and HHV8-associated (typically HIV-positive) versus idiopathic disease. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jeremy S. Abramson stated that rituximab is preferred as initial therapy for HHV8-positive disease, and chemotherapy can be added for patients with fulminant disease (antiretrovirals should always be used as well for those who are HIV-positive). Siltuximab is the preferred frontline therapy for idiopathic disease.Keywords
This publication has 5 references indexed in Scilit:
- Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman diseaseBlood, 2019
- Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseBlood, 2014
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman diseaseBlood, 2013
- Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB TrialJournal of Clinical Oncology, 2007